Yabao Pharmaceutical Group Co Ltd is a China-based company principally engaged in the research and development, production and sales of pharmaceutical products. The Company's main products include Chinese and Western medicine preparations, patches, active pharmaceutical ingredients and pharmaceutical packaging materials. The Company's products mainly involve pediatrics, adult medicines and health products. The Company sells its products under the brands of Yabao, Dinggui, Yabao Lishu and Yabao Weiyuan. The Company mainly operates its businesses in the domestic and overseas markets.

Employees

3,415

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
26-08-26	CN¥7.170	+2.43%	35,742,461
26-08-25	CN¥7.000	+3.24%	24,484,927
26-08-24	CN¥6.780	-1.31%	19,598,659
26-08-21	CN¥6.870	-3.92%	30,607,954
26-08-20	CN¥7.150	+2.29%	32,805,500

End-of-day quote Shanghai S.E.

More quotes

End-of-day quote Shanghai S.E. 2026-08-25			5-day change	1st Jan Change
7.000 ^CNY	+3.24%		-1.27%	+7.86%

07-31	Shanxi Yabao Pharmaceutical Logistics Distribution Co., Ltd. announced that it expects to receive CNY 50 million in funding from Yabao Pharmaceutical Group Co., Ltd	CI
07-31	Beijing Yabao Biopharmaceutical Co., Ltd. announced that it has received CNY 100 million in funding from Yabao Pharmaceutical Group Co., Ltd	CI

Market Cap	4.96B 738M 633M 594M 543M 1.02B 70.38B 1.03B 7.04B 2.73B 35.51B 2.77B 2.71B 118B	P/E 2024	18.1x	P/E 2025	14.2x
Enterprise Value	4.18B 621M 533M 501M 457M 863M 59.26B 867M 5.92B 2.3B 29.9B 2.33B 2.28B 99.02B	EV / Sales 2024	1.45x	EV / Sales 2025	1.65x
Free-Float	79.74%	Yield 2024	4.93%	Yield 2025	5.39%

07-31	Shanxi Yabao Pharmaceutical Logistics Distribution Co., Ltd. announced that it expects to receive CNY 50 million in funding from Yabao Pharmaceutical Group Co., Ltd	CI
07-31	Beijing Yabao Biopharmaceutical Co., Ltd. announced that it has received CNY 100 million in funding from Yabao Pharmaceutical Group Co., Ltd	CI
07-31	Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2026	CI
07-31	Yabao Pharmaceutical Group Co., Ltd announces an Equity Buyback for CNY 200 million worth of its shares.	CI
07-30	Yabao Pharmaceutical Group Co., Ltd authorizes a Buyback Plan.	CI
05-25	Yabao Pharmaceutical Subsidiary Secures Chinese Regulatory Approval for High Cholesterol Tablets	MT
04-24	Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-24	Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
12-21	Shanxi Tongxiang Times Technology Co., Ltd. completed the acquisition ofan additional 62% stake in Yabao Pharmaceutical Taiyuan Pharmaceutical Co., Ltd. from Yabao Pharmaceutical Group Co., Ltd.	CI
12-18	Yabao Pharma Gets Clinical Trial Nod for Pulmonary Arterial Hypertension Drug	MT
11-17	Tranche Update on Yabao Pharmaceutical Group Co., Ltd's Equity Buyback Plan announced on May 17, 2025.	CI
11-13	Yabao Pharmaceutical Group Co., Ltd's Equity Buyback announced on May 17, 2025, has closed with 8,000,000 shares, representing 1.14% for CNY 52.15 million.	CI
11-13	Yabao Pharmaceutical Obtains Registration for Children's Nutrition Product	MT

16-06-30	Yabao Pharmaceutical : Pharmaceuticals and LFB Biomedicaments Enter Into Strategic Partnership to Deliver VIALEBEX® (LFB’s Human Albumin) in China	BU
16-04-20	Yabao Pharmaceutical : Pharmaceuticals and Salus Pharma Announce Strategic Partnership for Generic Drugs	BU
16-01-12	Yabao Pharmaceuticals : and Sciecure Pharma Announce Strategic Partnership to Co-develop, Manufacture and Commercialize Generics for U.S. and China	BU
15-10-20	Yabao Pharmaceuticals : Enters Second Innovative Collaboration With Eli Lilly and Company to Develop Diabetes Treatment	BU
15-09-15	Yabao Pharmaceuticals : and Primary Peptides Announce Exclusive China Partnership	BU

Yabao Pharmaceutical Group Co., Ltd Stock

Stocks

600351

CNE000001CM5

Pharmaceuticals

Valuation: Yabao Pharmaceutical Group Co., Ltd

Chart: Yabao Pharmaceutical Group Co., Ltd

Latest news : Yabao Pharmaceutical Group Co., Ltd

Press Releases: Yabao Pharmaceutical Group Co., Ltd

News in other languages: Yabao Pharmaceutical Group Co., Ltd

Quotes and Performance

Price Extremes

Managers and Directors: Yabao Pharmaceutical Group Co., Ltd

Generic Pharmaceuticals

Financials

Company Profile

Quotes

1 day	+3.24%
1 week	-1.27%
Current month	+8.19%
1 month	+9.20%
3 months	+9.55%
6 months	+4.63%
Current year	+7.86%

1 week	6.72	7.22
1 month	6.33	7.45
Current year	5.6	7.45
1 year	5.6	7.45
3 years	4.94	9
5 years	4.94	11.9
10 years	4.5	11.9

Manager	Title	Age	Since
Wei Ren CEO	Chief Executive Officer	42	2019-04-22
Zhe Feng Zuo DFI	Director of Finance/CFO	54	2017-05-16
Peng Bo Ren PRN	Corporate Officer/Principal	53	2007-03-10

Director	Title	Age	Since
Wu Xian Ren CHM	Chairman	66	2005-05-25
Peng Bo Ren BRD	Director/Board Member	53	2014-05-14
Wei Ren BRD	Director/Board Member	42	2019-04-22

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
YABAO PHARMACEUTICAL GROUP CO., LTD	+3.24%	-1.27%	-4.24%	-6.67%	721M
SUN PHARMACEUTICAL INDUSTRIES LTD.	-1.17%	-0.03%	+18.70%	+70.05%	48.37B
OTSUKA HOLDINGS CO., LTD.	+0.33%	+1.78%	+55.45%	+123.50%	39.88B
CIPLA LIMITED	-1.36%	-1.36%	-11.21%	+14.14%	12.05B
ZYDUS LIFESCIENCES LIMITED	+2.27%	+4.12%	+16.41%	+81.30%	11.77B
KRKA, D. D.	+0.19%	0.00%	+30.98%	+150.00%	9.19B
GEDEON RICHTER	-0.45%	+3.26%	+24.53%	+45.36%	7.87B
ONO PHARMACEUTICAL CO., LTD.	-0.24%	+1.12%	+54.22%	-10.86%	7.25B
GLENMARK PHARMACEUTICALS LIMITED	+1.60%	+8.54%	+25.00%	+217.84%	7.1B
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.	+0.95%	-8.22%	-39.88%	+16.67%	5.26B
Average	+0.55%	+0.63%	+17.00%	+70.13%	14.95B
Weighted average by Cap.	-0.10%	+1.16%	+26.83%	+85.15%

	2024	2025
Net sales	2.69B 399M 343M 322M 294M 555M 38.1B 557M 3.81B 1.48B 19.22B 1.5B 1.47B 63.67B	2.24B 333M 286M 268M 245M 463M 31.78B 465M 3.18B 1.23B 16.03B 1.25B 1.22B 53.1B
Net income	243M 36.1M 30.98M 29.08M 26.56M 50.12M 3.44B 50.36M 344M 133M 1.74B 136M 133M 5.75B	320M 47.6M 40.85M 38.34M 35.02M 66.09M 4.54B 66.41M 454M 176M 2.29B 179M 175M 7.59B
Net Debt	-483M -71.82M -61.64M -57.86M -52.85M -99.73M -6.85B -100M -685M -265M -3.46B -270M -264M -11.45B	-784M -117M -100M -93.98M -85.84M -162M -11.13B -163M -1.11B -431M -5.61B -438M -429M -18.59B